Skip to content
10-Q

Quarterly Report

ADMA BIOLOGICS, INC. ADMA

0001140361-25-017747

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 238.73M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $71.63M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $103.15M
Current Liabilities Q1 2025 · Mar 31, 2025 $53.5M
Current Liabilities Q1 2025 · Dec 31, 2024 $55.54M
Total Liabilities Q1 2025 · Mar 31, 2025 $137.15M
Total Liabilities Q1 2025 · Dec 31, 2024 $139.66M
Current Assets Q1 2025 · Mar 31, 2025 $351.81M
Current Assets Q1 2025 · Dec 31, 2024 $331.41M
Total Assets Q1 2025 · Dec 31, 2024 $488.68M
Total Assets Q1 2025 · Mar 31, 2024 $350.88M
Shares Diluted Q1 2025 · Mar 31, 2024 236.41M sh
Capex Q1 2025 · Mar 31, 2024 $2.35M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$2.22M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.08
Eps Basic Q1 2025 · Mar 31, 2024 $0.08
Sga Expense Q1 2025 · Mar 31, 2024 $15.64M
Rd Expense Q1 2025 · Mar 31, 2024 $450K
Rd Expense restated Q1 2025 · Apr 1, 2019 $300K
Net Income Q1 2025 · Mar 31, 2024 $17.81M
Operating Income Q1 2025 · Mar 31, 2024 $21.82M
Gross Profit Q1 2025 · Mar 31, 2024 $39.11M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $42.77M
Revenue Q1 2025 · Mar 31, 2024 $81.88M
Stockholders Equity Q1 2025 · Dec 31, 2023 $135.21M